Guangzhou Baiyunshan Pharmaceutical Holdings (00874) subsidiary has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.
Baiyunshan (00874) announced that recently, its subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyun...
Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.
BYS30 granules is a class 1 innovative traditional Chinese medicine compound formulation developed by Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory, indicated for knee osteoarthritis.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
